KLK3 and ocular melanoma: Although there are no reported results of randomized controlled trials on OM-CRPC, several retrospective studies have reported favorable prostate-specific antigen (PSA) responses and delayed clinical progression with PSDT, suggesting that addition of targeting treatment for progressing lesions can be an effective treatment option for OM-CRPC, including our reports [14,15,16,17,18,19,20].